Protocol Ledger

NCT05473442 · Phase II · TERMINATED

Study of EQU-001 for Uncontrolled Focal Onset Seizures

Interventional Phase II clinical trial protocol NCT05473442 sponsored by Equilibre Biopharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-27 Enrollment: 27 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05473442
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)27 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05473442
Protocol FieldVerified Registry Value
NCT IdentifierNCT05473442
Consolidated Lead SponsorEquilibre Biopharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment27 participants (ACTUAL)
Registered Start Date2022-12-27
WhyStopped ClassificationFunding / COVID / Operational

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05473442
Hospital Research SiteLocationSite Profile
NYU Langone Health and Perlmutter Cancer CenterNew York, NYOpen Hospital Dossier ->
University of VirginiaCharlottesville, VAOpen Hospital Dossier ->
Hadassah Medical CenterJerusalem, IsraelOpen Hospital Dossier ->
Rabin Medical CenterPetah Tikva, IsraelOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI